Amgen plans to reduce its headcount by 12-14% or 2,200-2,600 staff in an effort to “create operational efficiencies” and support R&D investments. These initiatives, expected to yield savings of between $1 billion – $1.3 billion in 2008, are in part, due to lower Aranesp sales. Restructuring charges are expected to be $600 – $700 million in 2007 and 2008, which includes $289 million for asset impairment and related costs reported in the second quarter. With the r...